BerGenBio

Report Publication Announcement • Nov 6, 2020

BERGENBIO HOSTING VIRTUAL R&D DAY TODAY

BERGENBIO HOSTING VIRTUAL R&D DAY TODAY

Bergen, Norway, 06 November 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical need, is pleased to announce that it is hosting a Virtual

R&D Day today.

The online event will begin at 13.00pm CET (04.00am PST/06.00am CST). Please

click here (bergenbio@consilium

-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20E

vent) to register.

The event will feature experts from academic institutions across Europe and the

US, highlighting the role of AXL kinase as an essential mediator of the

biological mechanisms underlying life-threatening diseases, such as cancer,

fibrosis and infectious diseases, including COVID-19.

Each presentation will be followed by a Q&A session. Further details on the

presentations can be found in the agenda below.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "BerGenBio has

always been committed to pursuing excellence and innovation in R&D. We remain a

world leader in understanding the role and function of AXL biology, and with our

collaborators we have demonstrated that AXL is a key driver of immune evasive

and drug-resistant metastatic cancer, as well as other aggressive diseases. We

are grateful to all our speakers, who during today's event will be providing

insights into the latest AXL research, including the clinical benefit seen from

bemcentinib."

Agenda

(times in CET)

13:00  Introduction - Richard Godfrey, Chief Executive Officer,

BerGenBio

Presentations from

independent AXL

experts, followed

by Q&A sessions led

by Jim Lorens,

Chief Scientific

Officer and Hani

Gabra, Chief

Medical Officer at

BerGenBio

13:10 AXL in AML/MDS - Professor Sonja Loges, Director,

Department of Personalised Oncology, University Hospital

Mannheim and Division of Personalised Medical Oncology,

German Cancer Research Center - DKFZ (Heidelberg,

Germany)

13:40 AXL in lung cancer - Dr Matthew Krebs, Clinical Senior

Lecturer in Experimental Cancer Medicine and Honorary

Consultant in Medical Oncology, The Christie NHS

Foundation Trust (Manchester, UK)

14:10 AXL and viruses/COVID-19 - Professor Wendy Maury,

Professor of Microbiology and Immunology, University of

Iowa (Iowa City, USA)

14:40 AXL in fibrosis/IPF - Professor Cory Hogaboam, Professor

of Medicine, Cedars-Sinai Medical Center (Los Angeles,

USA)

15:10 Bemcentinib clinical development plan - Hani Gabra, Chief

Medical Officer, BerGenBio

15:25 Concluding remarks - Richard Godfrey, Chief Executive

Officer, BerGenBio

For further

information, please

contact Consilium

Strategic

Communications at

bergenbio@consilium

-comms.com or

ir@bergenbio.com

- END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the

biological mechanisms underlying life-threatening diseases. In cancer, AXL

suppresses the body's immune response to tumours and drives cancer treatment

failure across many indications. AXL expression defines a very poor prognosis

subgroup in most cancers. AXL inhibitors, therefore, have potential high value

at the centre of cancer combination therapy, addressing significant unmet

medical needs and multiple high-value market opportunities. Research has also

shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class

selective AXL inhibitor in a broad phase II clinical development programme.

Ongoing clinical trials are investigating bemcentinib in multiple solid and

haematological tumours, in combination with current and emerging therapies

(including immunotherapies, targeted therapies and chemotherapy), and as a

single agent. Bemcentinib targets and binds to the intracellular catalytic

kinase domain of AXL receptor tyrosine kinase and inhibits its activity.

Increase in AXL function has been linked to key mechanisms of drug resistance

and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in lung cancer,

leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,

tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is

developing a companion diagnostic test to identify patient populations most

likely to benefit from bemcentinib: this is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.